These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 29718278)
1. The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease. Chi LY; Zitomersky NL; Liu E; Tollefson S; Bender-Stern J; Naik S; Snapper S; Bousvaros A Inflamm Bowel Dis; 2018 May; 24(6):1344-1351. PubMed ID: 29718278 [TBL] [Abstract][Full Text] [Related]
2. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease. Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555 [TBL] [Abstract][Full Text] [Related]
3. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852 [TBL] [Abstract][Full Text] [Related]
4. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556 [TBL] [Abstract][Full Text] [Related]
5. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Zitomersky NL; Atkinson BJ; Fournier K; Mitchell PD; Stern JB; Butler MC; Ashworth L; Hauenstein S; Heiner L; Chuang E; Singh S; Bousvaros A Inflamm Bowel Dis; 2015 Feb; 21(2):307-14. PubMed ID: 25569737 [TBL] [Abstract][Full Text] [Related]
6. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127 [TBL] [Abstract][Full Text] [Related]
7. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855 [TBL] [Abstract][Full Text] [Related]
8. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD. Lega S; Phan BL; Rosenthal CJ; Gordon J; Haddad N; Pittman N; Benkov KJ; Dubinsky MC Inflamm Bowel Dis; 2019 Jan; 25(1):134-141. PubMed ID: 29868777 [TBL] [Abstract][Full Text] [Related]
9. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. Medicine (Baltimore); ; . PubMed ID: 25950682 [TBL] [Abstract][Full Text] [Related]